When PPARα activity is therapeutically induced with fenofibrate, a clinically approved PPARα agonist, the deleterious changes in hepatic fatty acid metabolism are reversed, blood ketone levels rise, and cachexia is prevented in mice with lung cancer (5). This evidence concerns the gene PPARA and lung carcinoma.